PFG Advisors Trims Stock Position in Stryker Corporation $SYK

PFG Advisors lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 39.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 11,322 shares of the medical technology company’s stock after selling 7,493 shares during the quarter. PFG Advisors’ holdings in Stryker were worth $3,979,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Clayton Financial Group LLC purchased a new position in Stryker during the 3rd quarter worth $26,000. United Financial Planning Group LLC purchased a new position in Stryker during the 3rd quarter worth $27,000. Strive Asset Management LLC acquired a new position in shares of Stryker during the 3rd quarter worth $30,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Stryker during the 3rd quarter worth $34,000. Finally, Copia Wealth Management grew its stake in shares of Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock worth $40,000 after purchasing an additional 69 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 1.5%

Shares of SYK stock opened at $338.15 on Tuesday. The firm has a market cap of $129.50 billion, a P/E ratio of 40.26, a PEG ratio of 2.01 and a beta of 0.92. Stryker Corporation has a 1-year low of $319.32 and a 1-year high of $404.87. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The firm’s 50-day simple moving average is $352.61 and its 200-day simple moving average is $359.31.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.07. The business had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company’s revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the firm posted $4.01 EPS. As a group, equities analysts forecast that Stryker Corporation will post 14.92 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. The Goldman Sachs Group lowered their price target on shares of Stryker from $403.00 to $357.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Evercore set a $390.00 price objective on shares of Stryker in a research note on Monday, January 5th. UBS Group lowered their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 17th. Leerink Partners initiated coverage on shares of Stryker in a research note on Monday, April 13th. They issued an “outperform” rating and a $410.00 price objective on the stock. Finally, Barclays reissued an “overweight” rating and issued a $469.00 price objective on shares of Stryker in a research note on Monday, February 2nd. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average target price of $421.11.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.